Cognitive Function After Treatment of Primary CNS Malignancy


About this study

The purpose of this study is to evaluate cognitive function and to determine neurocognitive assessment using a select CogState test battery in patients with primary intracranial malignancies receiving photon- or proton-based cranial irradiation with curative intent.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 4 years.
  • Able to use computer for assessment battery.
  • Receiving cranial photon- or proton-based radiation for primary central nervous system malignancy.
  • Histological or radiologic confirmation of intracranial disease.
  • ECOG Performance Status (PS) 0-2, Karnofsky PS 60-100, or Lansky/Play PS for Children 60-100.
  • Ability to complete clinical quality of life questionnaire(s) by themselves or with assistance.
  • Demonstrates the capacity to sign informed consent.
  • Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136*, **
    • * Patients do not need to agree to Registry blood draw.
    • **Patients at Mayo Clinic  Florida and Arizona can be enrolled without concurrent Registry consent.   

Exclusion Criteria:

  • Patients with WHO Grade IV astrocytoma or glioblastoma tumors.
    • Note: A patient with Grade IV tumors of other histology can participate in the study if they meet all other criteria.
    • Note: Diffuse Astrocytomas with molecular  features of glioblastoma are acceptable on study
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,  symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any prior intracranial radiation.
  • Patients receiving Gamma Knife radiosurgery.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nadia Laack, M.D.

Open for enrollment

Contact information:

Brianna Tranby M.A.

(507) 284-0276

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Sujay Vora, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


Jacksonville, Fla.

Mayo Clinic principal investigator

Daniel Trifiletti, M.D.

Open for enrollment

Contact information:

Anna Harrell B.S., M.P.H., CCRP

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer